Compare GDL & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GDL | TIL |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 90.7M | 74.7M |
| IPO Year | N/A | 2021 |
| Metric | GDL | TIL |
|---|---|---|
| Price | $8.44 | $8.07 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $125.00 |
| AVG Volume (30 Days) | 5.7K | ★ 21.2K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 6.02% | N/A |
| EPS Growth | N/A | ★ 6.06 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $8.01 | $5.67 |
| 52 Week High | $8.67 | $42.75 |
| Indicator | GDL | TIL |
|---|---|---|
| Relative Strength Index (RSI) | 52.82 | 43.12 |
| Support Level | $8.39 | $7.88 |
| Resistance Level | $8.45 | $9.03 |
| Average True Range (ATR) | 0.06 | 0.54 |
| MACD | 0.01 | -0.05 |
| Stochastic Oscillator | 75.05 | 32.61 |
GDL Fund is a diversified closed-end management investment company. Its primary investment objective is to achieve absolute returns in various market conditions without excessive risk of capital. The fund seeks to achieve its objective by investing in merger arbitrage transactions and, to a lesser extent, in corporate reorganizations involving stubs, spin-offs, and liquidations.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.